<DOC>
	<DOCNO>NCT01320722</DOCNO>
	<brief_summary>The investigator hypothesize , among non-hypertensive overweight obese individual , treatment vitamin D deficiency lower uric acid concentration ( either xanthine oxidase inhibition increase renal excretion ) attenuate renin angiotensin system ( RAS ) activation , improve endothelial function , low blood pressure .</brief_summary>
	<brief_title>Study Vitamin D Uric Acid Lowering Kidney Blood Vessel Function</brief_title>
	<detailed_description>We demonstrate low level 25-hydroxyvitamin D ( 25 [ OH ] D ) high concentration uric acid potentially modifiable factor independently associate increase risk develop hypertension ( high blood pressure ) human . Other investigator show vitamin D supplementation , lower uric acid allopurinol , may reduce blood pressure . Animal experiment suggest activation systemic local kidney-specific renin angiotensin system ( RAS ) may principal mechanism link 25 ( OH ) D uric acid hypertension . In human parallel animal study , show cross-sectional analysis non-hypertensive individual low 25 ( OH ) D high uric acid level increase activation systemic kidney-specific RAS , independent factor . However , whether vitamin D supplementation uric acid lower attenuates RAS activation never demonstrate human . Both low 25 ( OH ) D high uric acid concentration also associate endothelial dysfunction human , endothelial function may modulate RAS provide alternate mechanism development hypertension . It remain unclear , however , whether intervention increase 25 ( OH ) D decrease uric acid level among non-hypertensive adult improve endothelial function ; furthermore , unknown whether treatment individual would lower blood pressure . Determining whether treatment 25 ( OH ) D uric acid concentration , per se , attenuate RAS activation , improve endothelial function , low blood pressure among nonhypertensive individual critically important , implication stretch beyond hypertension prevention , since RAS activation , endothelial dysfunction , blood pressure also implicate pathology cardiovascular chronic kidney disease . Individuals overweight obese ( two-thirds US adult ) represent important population know low 25 ( OH ) D level , high uric acid concentration , activation RAS , endothelial dysfunction , increase risk hypertension , cardiovascular disease , chronic kidney disease . Interestingly , preliminary data demonstrate among overweight obese individual normal 25 ( OH ) D low uric acid level , adiposity longer associate activation RAS , suggest low 25 ( OH ) D high uric acid concentration might mediator adverse consequence overweight obesity .</detailed_description>
	<mesh_term>Overweight</mesh_term>
	<mesh_term>Vitamins</mesh_term>
	<mesh_term>Vitamin D</mesh_term>
	<mesh_term>Ergocalciferols</mesh_term>
	<mesh_term>Allopurinol</mesh_term>
	<mesh_term>Probenecid</mesh_term>
	<mesh_term>Uric Acid</mesh_term>
	<criteria>25 ( OH ) D &lt; 20 ng/mL OR Uric acid ≥ 5 mg/dL Age ≥ 18 , ≤ 75 year BMI ≥ 25 Hypertension , BPlowering medicine Diabetes Coronary Heart Disease estimate glomerular filtration rate ( EGFR ) &lt; 60 mL/min Kidney stone Active cancer ( except nonmelanoma skin cancer ) Pregnant Taking vitamin D supplement unwilling stop Osteoporosis Hypo hypercalcemia Hypo hyperphosphatemia Known allergy ACEinhibitors Taking medication hyperuricemia Gout , anemia , cirrhosis , active/chronic hepatitis , abnormal aspartate aminotransferase ( AST ) , alanine aminotransferase ( ALT ) total bilirubin level , anemia Known allergy either allopurinol probenecid Current use didanosine , azothioprine , methotrexate , ketoprofen , ketorolac , mycophenolate , ACEinhibitors</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>renin angiotensin system</keyword>
	<keyword>vitamin D</keyword>
	<keyword>uric acid</keyword>
	<keyword>allopurinol</keyword>
	<keyword>probenecid</keyword>
	<keyword>endothelial function</keyword>
</DOC>